LONG BEACH, Calif. / Jan 04, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the fourth quarter and year ended December 31, 2023.
Molina Healthcare will issue its earnings release for the fourth quarter and year ended December 31, 2023, after the market closes on Wednesday, February 7, 2024, and will host a conference call and webcast to discuss the earnings release on Thursday, February 8, 2024, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 4221213. A telephonic replay of the conference call will be available through Thursday, February 15, 2024, by dialing (877) 344-7529 and entering the confirmation number, 3687293.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed health care services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.2 million members as of September 30, 2023, located across 19 states. For more information about Molina Healthcare, please visit molinahealthcare.com.
Last Trade: | US$327.48 |
Daily Change: | -3.64 -1.10 |
Daily Volume: | 306,526 |
Market Cap: | US$19.190B |
July 23, 2024 July 19, 2024 April 11, 2024 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB